MENDELIAN RANDOMIZATION (MR) IN CARDIOVASCULAR DISEASE (CVD)

Prepared by **Dr. Sidhartha Mullapudi**, DrNB (Cardiology), MD (General Medicine)

I THE CONCEPTUAL RATIONALE: "NATURE'S RANDOMIZED CONTROLLED TRIAL"

- **Limitations of Observational Epidemiology:** Conventional observational cohort studies cannot definitively establish whether a biomarker is a **causal driver** of cardiovascular disease or merely a bystander because of **residual confounding** (unmeasured lifestyle, socioeconomic, or inflammatory factors) and **reverse causation** (the disease process itself alters the biomarker concentration).
- **The Mendelian Randomization (MR) Principle:** MR is an epidemiological study design that utilizes germline genetic variants—typically **Single Nucleotide Polymorphisms (SNPs)**—as **instrumental variables** for a modifiable exposure (such as LDL-C, HDL-C, Lp(a), or blood pressure) to test its causal effect on a clinical outcome (such as myocardial infarction or stroke).
- **Analogy to a Randomized Controlled Trial (RCT):** According to **Mendel's Second Law (Law of Independent Assortment)** and random segregation of alleles during meiosis at conception, individuals are randomly allocated to inherit exposure-raising versus exposure-lowering alleles independently of postnatal environmental or behavioral confounders, and because germline DNA sequence is fixed at conception, **reverse causation is impossible**.
- **Crucial Distinction (Lifelong Cumulative Exposure vs. Short-Term Trial Exposure):** Because genetic variants exert a lifelong cumulative effect from birth ("**cholesterol-years**" or "**mmHg-years**"), a genetically determined 38.7 mg/dL (1 mmol/L) lower LDL-C via MR reduces CAD risk by **50 to 55 percent**, whereas achieving the same 1 mmol/L LDL-C reduction for 5 years in a statin RCT reduces CAD risk by **22 percent** (per the CTT Collaboration)—demonstrating that **both magnitude and duration ("earlier is better")** dictate atherosclerotic burden.

II THE THREE CARDINAL INSTRUMENTAL VARIABLE ASSUMPTIONS

- **The Relevance Assumption:** The genetic variant (instrumental variable) must be **robustly and reproducibly associated with the exposure of interest** (quantified statistically by a first-stage **F-statistic greater than 10** to avoid "weak instrument bias").
- **The Independence (Exchangeability) Assumption:** The genetic variant must **not be associated with any measured or unmeasured confounding factors** (e.g., ancestry/population stratification or assortative mating) that influence the relationship between the exposure and the clinical outcome.
- **The Exclusion Restriction (No Horizontal Pleiotropy) Assumption:** The genetic variant must affect the clinical outcome **exclusively through the exposure of interest**, and not via any alternative independent biological pathway.

III LANDMARK MENDELIAN RANDOMIZATION EVIDENCE IN CARDIOLOGY

Cardiovascular Biomarker	Key Genetic Instruments Studied	Mendelian Randomization Verdict	Correlation with Landmark Phase III RCTs
LDL-Cholesterol / ApoB	*LDLR, PCSK9* (Cohen & Hobbs LOF), *HMGCR, NPC1L1, APOB*	**Strongly Causal** (~54% CAD reduction per lifelong 1 mmol/L lower LDL-C)	Concordant with **CTT Statin meta-analyses, IMPROVE-IT, FOURIER, and ODYSSEY OUTCOMES**; proved **ApoB** particle number is the primary driver
HDL-Cholesterol	*LIPG* (endothelial lipase Asn396Ser) & 14-SNP HDL genetic score (Voight et al., *Lancet* 2012)	**Non-Causal** (genetically higher isolated HDL-C does NOT reduce MI risk)	Explained the clinical failure of HDL-raising drugs: **AIM-HIGH / HPS2-THRIVE** (Niacin) and **ILLUMINATE / dal-OUTCOMES / ACCELERATE** (CETP inhibitors)
Triglyceride-Rich Lipoproteins (TRLs)	*LPL* (lipoprotein lipase), *APOA5, APOC3, ANGPTL3, ANGPTL4*	**Causal** (via remnant cholesterol and ApoB particles)	Validated development of **APOC3 inhibitors (Olezarsen, Plozasiran)** and **ANGPTL3 inhibitors (Evinacumab, Zodasiran)**
Lipoprotein(a) [Lp(a)]	*LPA* gene locus SNPs & **Kringle IV Type 2 (KIV-2) copy number repeats** (Kamstrup et al.; Clarke et al.)	**Directly Causal** for ASCVD and **Calcific Aortic Valve Stenosis**	Triggered Phase III ASO/siRNA trials (**Lp(a)HORIZON** with pelacarsen [missed primary MACE in Sept 2026]; ongoing **OCEAN(a)-Outcomes** with olpasiran & **ACCLAIM-Lp(a)** with lepodisiran)
C-Reactive Protein vs. IL-6 Signaling	*CRP* gene promoter variants vs. *IL6R* Asp358Ala variant	**CRP is Non-Causal** (bystander marker); **Upstream IL-1beta / IL-6R pathway is Causal**	Validated **CANTOS** (canakinumab anti-IL-1b reduced MACE) while proving hepatic CRP molecule itself does not cause plaque rupture

IV ADVANCED MENDELIAN RANDOMIZATION METHODOLOGIES

- **Two-Sample MR:** Extracts genetic variant-to-exposure associations from one large Genome-Wide Association Study (GWAS) consortium and genetic variant-to-outcome associations from a second independent GWAS consortium (such as CARDIoGRAMplusC4D or UK Biobank), dramatically increasing statistical power without requiring biomarker measurements in the outcome cohort.
- **Multivariable MR (MVMR):** Simultaneously models genetic instruments for multiple correlated exposures (for example, separating **LDL-C, Triglycerides, and Apolipoprotein B**); **Ference et al. (*JAMA* 2019)** used MVMR to prove that the clinical benefit of lowering both LDL-C and triglycerides is directly proportional to the absolute reduction in **Apolipoprotein B (ApoB)-containing lipoprotein particles**.
- **Cis-Mendelian Randomization ("Drug-Target MR"):** Restricts genetic instruments strictly to *cis*-acting variants located within or immediately adjacent to the gene encoding a pharmacological drug target (e.g., *HMGCR* for statins, *NPC1L1* for ezetimibe, *PCSK9* for PCSK9 inhibitors, *CETP* for CETP inhibitors, and *ACLY* for bempedoic acid). Accurately predicts **both trial efficacy** (e.g., additive LDL lowering of *HMGCR* + *NPC1L1* or *PCSK9*) and **on-target adverse effects** (such as the slight increase in **new-onset Type 2 Diabetes** observed with genetic *HMGCR, NPC1L1*, and *PCSK9* inhibition) before Phase III trials are completed.
- **Statistical Sensitivity Analyses for Pleiotropy: MR-Egger Regression** (where a non-zero y-intercept detects directional horizontal pleiotropy), **Weighted Median MR**, and **MR-PRESSO** (Pleiotropy Residual Sum and Outlier test).

V LIMITATIONS AND METHODOLOGICAL PITFALLS

- **Horizontal vs. Vertical Pleiotropy: Horizontal pleiotropy** occurs when a genetic variant influences the outcome through an independent biological pathway bypassing the exposure of interest, violating the exclusion restriction assumption and creating false causality. (In contrast, **vertical pleiotropy**—where the variant alters exposure A, which in turn alters downstream mediator B on the same causal pathway to the outcome, such as *IL6R* -> CRP—is valid and defines biological mechanisms.)
- **Canalization (Developmental Buffering):** Physiological compensatory adaptations during fetal and childhood development in response to a lifelong genetic variant may attenuate or mask the true adult effect of modifying the target.
- **Population Stratification and Dynastic Effects:** Differences in allele frequencies and disease prevalence across ancestral sub-populations can introduce confounding unless analyses are restricted to homogeneous ancestry or adjusted for genetic principal components.

VI PRACTICAL APPLICATION IN THE INDIAN CLINICAL CONTEXT

- **Deconstructing the South Asian ASCVD Phenotype:** South Asians experience myocardial infarction 5 to 10 years earlier than Western populations despite often having only moderately elevated total LDL-C. Mendelian randomization and genomic studies demonstrate that **elevated Lipoprotein(a)**, **atherogenic triglyceride-rich remnant particles (high ApoB-to-LDL-C ratio)**, and **genetically determined visceral adiposity (high waist-to-hip ratio / insulin resistance)** are potent causal drivers of premature CAD in Indians.
- **Guideline Translation (LAI / CSI / ESC Lipid Consensus):** Because MR proves that **lifelong cumulative ApoB exposure** and **Lp(a)** causally drive premature plaque burden, Indian and European guidelines recommend **universal once-in-a-lifetime measurement of Lipoprotein(a)** and earlier initiation of lipid-lowering therapy targeting **ApoB and Non-HDL-C** in high-risk South Asians.

KEY REFERENCES

- **Ference BA, Ginsberg HN, Graham I, et al.:** Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, *European Heart Journal*, 2017.
- **Voight BF, Peloso GM, Orho-Melander M, et al.:** Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, *The Lancet*, 2012.
- **Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG:** Genetically elevated lipoprotein(a) and increased risk of myocardial infarction, *JAMA*, 2009.
- **Ference BA, Kastelein JJP, Ray KK, et al.:** Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease, *JAMA*, 2019. **LAST REVIEWED: October 2026**